2026 Update: Hims No Longer Offers Compounded Tirzepatide
Following the FDA's removal of tirzepatide from the drug shortage list and subsequent enforcement against mass 503B compounding, Hims pulled its compounded tirzepatide listings entirely. Hims now sells brand-name Zepbound (Eli Lilly's tirzepatide) instead — but at approximately $1,899 per month, a price that is nearly six times higher than Eli Lilly's own LillyDirect self-pay price of $299 to $449 per month for the same medication. This review reflects the current situation and explains why the comparison has changed fundamentally from Hims' earlier compounded-tirzepatide positioning.
What Changed: From Compounded Tirzepatide to Marked-Up Brand Zepbound
Hims previously offered compounded tirzepatide — the same active pharmaceutical molecule as Zepbound and Mounjaro — through its telehealth platform at dose-tier pricing similar to many other compounded GLP-1 providers. Following the FDA's 2024–2025 removal of tirzepatide from the drug shortage list, which ended the broad legal window for mass compounding, Hims pulled its compounded tirzepatide listings and pivoted to compounded semaglutide (a slightly different regulatory situation) and, separately, its own branded weight loss programs.
For tirzepatide specifically, Hims now offers brand-name Zepbound, made by Eli Lilly, at approximately $1,899 per month. This is a striking price point: Eli Lilly's own LillyDirect self-pay program, effective December 1, 2025, charges $299/month for the 2.5 mg starting dose, $399/month for the 5 mg dose, and $449/month for all other approved doses (7.5 mg through 15 mg) through the Zepbound Self Pay Journey Program. Hims' price is roughly four to six times higher than buying the identical FDA-approved medication directly from the manufacturer.
Hims Tirzepatide Pricing Snapshot (2026)
Hims — Brand Zepbound Pricing
★ Luma Health — Tirzepatide Pricing
Why Hims' Zepbound Price Is So Much Higher Than Eli Lilly's Own Direct Price
Hims' Genuine Strengths and Honest Limitations for Tirzepatide (2026)
✓ Genuine Strengths
- Large, publicly traded company (NYSE: HIMS) — institutional stability
- Polished app experience with weight tracking and provider messaging
- Multi-condition platform — convenient for existing Hims users
- Offers the FDA-approved brand-name product (Zepbound), not a compounded alternative
- Established consumer brand with years of telehealth track record
⚠ Honest Limitations
- Compounded tirzepatide no longer available at any price
- Brand Zepbound priced at ~$1,899/month — a severe markup over LillyDirect's $299–$449/month
- No apparent pathway to LillyDirect-equivalent self-pay pricing through Hims
- Generalist platform — not GLP-1 or tirzepatide specialist
- Pricing structure has changed multiple times in 2026 — verify before enrolling
Hims Tirzepatide vs Luma Health: Direct Comparison
| Factor | Hims (Brand Zepbound) | Luma Health (Compounded Tirz) |
|---|---|---|
| Medication type | FDA-approved brand (Zepbound) | Compounded tirzepatide |
| Self-pay monthly price | ~$1,899/mo | $297/mo flat |
| Same medication elsewhere, cheaper | LillyDirect: $299–$449/mo | N/A |
| Dose-tier increases | N/A (single price advertised) | None — flat at every dose |
| 12-mo cost | ~$22,788 | $3,564 flat |
| Pharmacy named publicly | Eli Lilly (brand), via Hims markup | ✓ VialsRX, TX #35264, verifiable |
| Clinical provider named | Hims network | ✓ Wasef Health, PC |
| Company size / stability | ✓ NYSE listed | Newer platform |
Who Should Consider Hims vs. Luma Health for Tirzepatide
Hims Might Still Make Sense If...
- You already use Hims for other health needs and specifically want everything managed on one platform, and cost is not your primary concern
- You have not yet compared Hims' Zepbound price to LillyDirect's self-pay program — do this before enrolling, as the savings are substantial
- Your insurance covers Zepbound and you're using Hims' platform mainly for the clinical evaluation rather than for medication pricing
★ Luma Health Is the Better Fit If...
- You want compounded tirzepatide at a flat, predictable rate — $297/month at every dose tier from 2.5 mg through 15 mg/week
- Pharmacy transparency before you pay matters — VialsRX (TX #35264) is publicly named and independently verifiable at pharmacy.texas.gov
- You do not have insurance coverage for brand-name Zepbound and want the most cost-effective legitimate pathway to the tirzepatide molecule
- No contracts, no commitment periods — cancel any month without penalty
The tirzepatide molecule.
$297/mo flat, no markup.
Compounded tirzepatide $297/month flat. VialsRX pharmacy (TX Board #35264). No contracts. Wasef Health, PC clinical oversight.
Start With Luma Health →Frequently Asked Questions
No. Hims pulled its compounded tirzepatide listings following the FDA's removal of tirzepatide from the drug shortage list, which ended the broad legal window for mass compounding of the drug. Hims pivoted to compounded semaglutide (a different regulatory situation) and to its own branded weight loss offerings, including brand-name Zepbound. If you specifically want compounded tirzepatide, Hims is no longer a pathway to that; Luma Health continues to offer it at $297/month flat.
Hims has offered brand-name Zepbound at approximately $1,899/month self-pay. This is significantly higher than Eli Lilly's own LillyDirect self-pay pricing for the identical medication, which runs $299/month (2.5 mg dose), $399/month (5 mg dose), or $449/month (7.5–15 mg doses) as of the program's December 2025 pricing update. Always verify current Hims pricing directly at hims.com, and compare it against LillyDirect before enrolling anywhere.
Hims is a telehealth platform that adds its own markup, clinical service fee, and convenience packaging on top of the wholesale medication cost, rather than passing through Eli Lilly's own reduced self-pay pricing. LillyDirect is Eli Lilly's own direct-to-consumer channel, which offers the medication at a price the manufacturer has set specifically to improve affordability. The roughly 4x to 6x price gap reflects the difference between a manufacturer's own discounted direct channel and a third-party telehealth markup on the same product.
Yes, in nearly every scenario. If you want the brand-name product, LillyDirect's own self-pay program ($299–$449/month) or, if insured, the Lilly Zepbound Savings Card (as low as $25/month with qualifying coverage) are both far less expensive than Hims' current pricing. If you want the tirzepatide molecule via a compounded pathway, Luma Health offers it at $297/month flat across all dose tiers, with no insurance required.
Yes. Hims remains a legitimate, publicly traded telehealth company (NYSE: HIMS) with licensed clinical infrastructure. The medication it currently offers for tirzepatide — brand-name Zepbound — is a genuine, FDA-approved product. The concern is not legitimacy but value: Hims' self-pay price for that product is substantially higher than pricing available directly from the manufacturer or through a compounded alternative.
Yes. Complete Luma Health's intake at start.mylumahealth.com while you still have medication remaining from your current source. Inform your Wasef Health, PC provider of your current tirzepatide dose and how long you've been at that dose — no titration restart is required, since the active ingredient is the same. Wait for VialsRX shipping confirmation (5–10 business days) before canceling your prior plan.
References
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205–216. PubMed 35658024
- Aronne LJ, et al. Continued Treatment with Tirzepatide for Maintenance of Weight Reduction (SURMOUNT-4). JAMA. 2024;331(1):38–48. PubMed 38078870
- Eli Lilly and Company. Lilly Lowers the Price of Zepbound Single-Dose Vials. Press Release, December 1, 2025. investor.lilly.com
- Physicians Weekly. Hims & Hers Adds Zepbound at $1,899 vs Lilly $349. physiciansweekly.com
- FDA. Zepbound (tirzepatide) Prescribing Information. FDA.gov
- U.S. Food and Drug Administration. Human Drug Compounding — Section 503A. FDA.gov
- Hims & Hers Health. Weight Loss Program. hims.com
- NIDDK. Prescription Medications to Treat Overweight & Obesity. niddk.nih.gov